Safety and Efficacy of Doxofylline for Treating the Patients With Ticagrelor Caused Dyspnea
10.3969/j.issn.1000-3614.2017.09.013
- VernacularTitle:多索茶碱治疗替格瑞洛相关呼吸困难的安全性和有效性分析
- Author:
mei Ya LIU
1
;
ying Zhan HAN
;
le Xu WANG
;
guang Chun QIU
;
jie Wen LU
;
Bo CHENG
Author Information
1. 郑州大学第一附属医院 心内科
- Keywords:
Dyspnea;
Ticagrelor;
Doxofylline
- From:
Chinese Circulation Journal
2017;32(9):886-888
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the safety and efficacy of doxofylline for treating the patients with ticagrelor caused dyspnea.Methods:A total 172 coronary artery disease (CAD) patients with ticagrelor caused dyspnea in our hospital from 2015-02 to 2016-07 were studied.The patients were divided into 2 groups:Intervention group,patients received doxofylline at 200 mg twice per day for 5 days and Control group,patients received placebo.n=86 in each group.Dyspnea remission rate of was recorded at 1 day after treatment;platelet aggregation rate before and after treatment,cardiac death,myocardial infarction (MI),stroke,bleeding and other adverse cardiovascular and cerebral events were compared at 6 month after treatment.Results:Compared with Control group,Intervention group had improved dyspnea remission rate at 1 day after treatment (93％ vs 63％),P＜0.05;platelet aggregation rate [before doxofylline application:(35.53±5.1)％ vs (35.16±4.6)％,after doxofylline application:(26.48±4.3)％ vs(25.98±4.7)％]adverse cardiovascular and cerebral events were similar between 2 groups before and after doxofylline application,P＞0.05.Conclusion:Doxofylline was effective for treating the patients with ticagrelor caused dyspnea,it does not affect platelet aggregation effect of ticagrelor.
